{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:28:51Z","timestamp":1789086531568,"version":"build-2803163510"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"},{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research & Development, LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jsm.jsexmed.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,2,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Dapoxetine (DPX) has a pharmacokinetic profile suggesting a low rate of class-related adverse events (AEs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aim<\/jats:title>\n                  <jats:p>To assess the incidence of treatment emergent AEs (TEAEs) of special interest (known associations with selective serotonin reuptake inhibitors and\/or potential clinically relevant AEs), and the related discontinuation rate in patients with premature ejaculation (PE) treated with DPX or alternate oral treatment (AOT), in routine clinical practice.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In a prospective, 12-week, open-label, postmarketing observational, multinational study (PAUSE), 7545 patients were enrolled and divided into 2 groups: DPX 30\u201360 mg and AOT.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main outcome measures<\/jats:title>\n                  <jats:p>The incidence rate of predefined TEAEs of special interest (mood and related, neurocognitive related, cardiovascular, urogenital and sexual function, accidental injury, and abnormal bleeding) in the DPX and the AOT groups, and the rate of AEs leading to study discontinuation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The safety analysis was performed on 6128 patients treated with DPX and 1417 with AOT. The incidence of TEAEs of special interest in each AE category was greater for patients treated with AOT than with DPX. The higher differences were observed in the neurocognitive-related category (DPX 1.9% vs AOT 4.7%; P &amp;lt; .001), in the mood and related category (DPX 0.4% vs AOT 1.1%; P &amp;lt; .001), and in the urogenital system\/sexual function (DPX 0.4% vs AOT 0.8%; P = .04). Cardiovascular TEAEs were the only AEs numerically greater in the DPX group (1.3 vs 1.6%, P = .34). The overall discontinuation rate was 10.9% in the DPX group and 6.9% in the AOT group).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>DPX has a favorable safety profile in terms of class-related TEAEs and clinically relevant AEs of special interest. In particular, it shows a significantly better safety profile in mood and related AEs, neurocognitive-related AEs, urogenital system, and sexual function, compared to the AOT group in the study population.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1016\/j.jsxm.2015.12.017","type":"journal-article","created":{"date-parts":[[2016,1,21]],"date-time":"2016-01-21T18:00:00Z","timestamp":1453399200000},"page":"194-199","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Comparison of Treatment of Emergent Adverse Events in Men with Premature Ejaculation Treated with Dapoxetine and Alternate Oral Treatments: Results From a Large Multinational Observational Trial"],"prefix":"10.1093","volume":"13","author":[{"given":"Paolo","family":"Verze","sequence":"first","affiliation":[{"name":"Department of Urology \u00a0 , Naples, , Italy"},{"name":"University of Naples, Federico II \u00a0 , Naples, , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Cai","sequence":"additional","affiliation":[{"name":"Urology Unit \u00a0 , Trento, , Italy"},{"name":"Santa Chiara Hospital \u00a0 , Trento, , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Magno","sequence":"additional","affiliation":[{"name":"Department of Urology \u00a0 , Messina, , Italy"},{"name":"University of Messina \u00a0 , Messina, , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Sabella","sequence":"additional","affiliation":[{"name":"Department of Urology \u00a0 , Naples, , Italy"},{"name":"University of Naples, Federico II \u00a0 , Naples, , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito","family":"Cucchiara","sequence":"additional","affiliation":[{"name":"Department of Urology \u00a0 , Naples, , Italy"},{"name":"University of Naples, Federico II \u00a0 , Naples, , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Palmieri","sequence":"additional","affiliation":[{"name":"Department of Urology \u00a0 , Naples, , Italy"},{"name":"University of Naples, Federico II \u00a0 , Naples, , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Mirone","sequence":"additional","affiliation":[{"name":"Department of Urology \u00a0 , Naples, , Italy"},{"name":"University of Naples, Federico II \u00a0 , Naples, , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,2,1]]},"reference":[{"issue":"Suppl 6","key":"2024032601020866600_bib1","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1097\/00004850-199807006-00003","article-title":"Serotonin, serotonergic receptors, selective serotonin reuptake inhibitors and sexual behaviour","volume":"13","author":"Olivier","year":"1998","journal-title":"Int Clin Psychopharmacol"},{"key":"2024032601020866600_bib2","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/S0022-5347(01)65467-3","article-title":"The efficacy of fluoxetine in the treatment of premature ejaculation: A double-blind placebo-controlled study","volume":"156","author":"Kara","year":"1996","journal-title":"J Urol"},{"key":"2024032601020866600_bib3","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/00004714-199510000-00006","article-title":"Sertraline treatment for premature ejaculation","volume":"15","author":"Mendels","year":"1995","journal-title":"J Clin Psychopharmacol"},{"key":"2024032601020866600_bib4","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1111\/j.1743-6109.2011.02386.x","article-title":"Oral agents for the treatment of premature ejaculation: review of efficacy and safety in the context of the recent International Society for Sexual Medicine criteria for lifelong premature ejaculation","volume":"8","author":"McMahon","year":"2011","journal-title":"J Sex Med"},{"key":"2024032601020866600_bib5","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1185\/030079906X132415","article-title":"Remission, dropouts, and adverse drug reaction rates in major depressive disorder: A meta-analysis of head-to-head trials","volume":"22","author":"Machado","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"2024032601020866600_bib6","first-page":"1245","article-title":"Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis","volume":"159","author":"Trindade","year":"1998","journal-title":"Can Med Assoc J"},{"key":"2024032601020866600_bib7","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/ijir.2014.37","article-title":"Antidepressant treatment of premature ejaculation: discontinuation rates and prevalence of side effects for dapoxetine and paroxetine in a naturalistic setting","volume":"27","author":"Jern","year":"2014","journal-title":"Int J Impot Res"},{"key":"2024032601020866600_bib8","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1177\/0091270005284850","article-title":"Single- and multiple-dose pharmacokinetics of dapoxetine hydrochloride, a novel agent for the treatment of premature ejaculation","volume":"46","author":"Modi","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"2024032601020866600_bib9","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1177\/1756287212453866","article-title":"Dapoxetine: a new option in the medical management of premature ejaculation","volume":"4","author":"McMahon","year":"2012","journal-title":"Ther Adv Urol"},{"key":"2024032601020866600_bib10","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.eururo.2013.08.018","article-title":"Results from a prospective observational study of men with premature ejaculation treated with dapoxetine or alternate care: the PAUSE study","volume":"65","author":"Mirone","year":"2014","journal-title":"Eur Urol"},{"key":"2024032601020866600_bib11","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/j.1743-6109.2010.02097.x","article-title":"Efficacy and safety of dapoxetine for the treatment of premature ejaculation: integrated analysis of results from five phase 3 trials","volume":"8","author":"McMahon","year":"2011","journal-title":"J Sex Med"},{"key":"2024032601020866600_bib12","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/j.1464-410X.2008.08165.x","article-title":"Treatment benefit of dapoxetine for premature ejaculation: results from a placebo-controlled phase III trial","volume":"103","author":"Kaufman","year":"2009","journal-title":"BJU Int"},{"key":"2024032601020866600_bib13","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.eururo.2009.01.025","article-title":"Dapoxetine for the treatment of premature ejaculation: results from a randomized, double-blind, placebo-controlled phase 3 trial in 22 countries","volume":"55","author":"Buvat","year":"2009","journal-title":"Eur Urol"},{"issue":"1Pt 1","key":"2024032601020866600_bib14","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1743-6109.2009.01560.x","article-title":"Treatment of premature ejaculation in the AsiaPacific region: results from a phase III double-blind, parallel-group study of dapoxetine","volume":"7","author":"McMahon","year":"2010","journal-title":"J Sex Med"},{"key":"2024032601020866600_bib15","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1111\/j.1743-6109.2010.01820.x","article-title":"Baseline characteristics and treatment outcomes for men with acquired or lifelong premature ejaculation with mild or no erectile dysfunction: integrated analyses of two phase 3 dapoxetine trials","volume":"7","author":"Porst","year":"2010","journal-title":"J Sex Med"},{"key":"2024032601020866600_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/11587660-000000000-00000","article-title":"Cardiovascular safety profile of dapoxetine during the premarketing evaluation","volume":"11","author":"Kowey","year":"2011","journal-title":"Drugs R D"},{"issue":"3 Suppl B","key":"2024032601020866600_bib17","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1177\/0269881198012003041","article-title":"Selective serotonin reuptake inhibitors in the treatment of affective disorders \u2013 III. Tolerability, safety and pharmacoeconomics","volume":"12","author":"Goldstein","year":"1998","journal-title":"J Psychopharmacol"},{"key":"2024032601020866600_bib18","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.2174\/1381612043383872","article-title":"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?","volume":"10","author":"Pacher","year":"2004","journal-title":"Curr Pharm Des"},{"key":"2024032601020866600_bib19","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1177\/070674370605101408","article-title":"Adverse cardiovascular events in antidepressant trials involving high-risk patients: a systematic review of randomized trials","volume":"51","author":"Swenson","year":"2006","journal-title":"Can J Psychiatry"},{"key":"2024032601020866600_bib20","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/sj.ijir.3900918","article-title":"The efficacy of citalopram in the treatment of premature ejaculation: A placebo-controlled study","volume":"14","author":"Atmaca","year":"2002","journal-title":"Int J Impot Res"},{"key":"2024032601020866600_bib21","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s11255-006-6659-2","article-title":"The efficacy of duloxetine in the treatment of premature ejaculation","volume":"39","author":"Athanasios","year":"2007","journal-title":"Int Urol Nephrol"},{"issue":"Suppl 4","key":"2024032601020866600_bib22","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1743-6109.2011.02451.x","article-title":"An overview of pharmacotherapy in premature ejaculation","volume":"8","author":"Porst","year":"2011","journal-title":"J Sex Med"},{"key":"2024032601020866600_bib23","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0090-4295(02)01606-0","article-title":"Quality of life and erectile dysfunction","volume":"59","author":"Althof","year":"2002","journal-title":"Urology"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609515000521?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609515000521?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/13\/2\/194\/48192417\/jsm_13_2_194.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/13\/2\/194\/48192417\/jsm_13_2_194.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T01:51:24Z","timestamp":1711417884000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/13\/2\/194\/6940031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,1]]},"references-count":23,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2016,2,1]]},"published-print":{"date-parts":[[2016,2,1]]}},"URL":"https:\/\/doi.org\/10.1016\/j.jsxm.2015.12.017","relation":{},"ISSN":["1743-6109","1743-6095"],"issn-type":[{"value":"1743-6109","type":"electronic"},{"value":"1743-6095","type":"print"}],"subject":[],"published-other":{"date-parts":[[2016,2]]},"published":{"date-parts":[[2016,2,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of Treatment of Emergent Adverse Events in Men With Premature Ejaculation Treated With Dapoxetine and Alternate Oral Treatments: Results From a Large Multinational Observational Trial","name":"articletitle","label":"Article Title"},{"value":"The Journal of Sexual Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsxm.2015.12.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}